FIELD: pharmaceutical engineering. SUBSTANCE: tablet has an active ingredient like tolfenamic acid or its pharmaceutically acceptable salts. The active ingredient has mean size of particles not exceeding 10 mcm. The tablet also contains alginic acid or its pharmaceutically acceptable salt in the amount of 1.5-6.0 mas.% and a superdisintegrator ingredient in the amount of 6 mas.% or more. Specific features of method for producing tablets containing tolfenamic acid or its pharmaceutical salts are also described. EFFECT: maximum tolfenamic acid concentration in blood plasma. 13 cl, 8 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL DRUG FORM FOR PERORAL INTRODUCTION TO REDUCE INTER-INDIVIDUAL VARIABILITY, IN PARACETAMOL-CONTAINING COMPOSITIONS IN PATIENT | 2009 |
|
RU2517139C2 |
| PHARMACEUTICAL PREPARATIONS WITH FIXED COMBINATION OF ANALGESIC AND ANTISPASMODIC AGENTS DOSES | 2015 |
|
RU2704613C2 |
| SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING INTEGRASE INHIBITOR | 2010 |
|
RU2602865C2 |
| SOLID FORMULATIONS OF OSPEMIFENE | 2005 |
|
RU2675624C2 |
| RANITIDINE TABLET COVERED BY HYDROXYPROPYLMETHYLCELLULOSE AND A METHOD OF COVER APPLYING | 1995 |
|
RU2117476C1 |
| HIGH DOSAGE STRENGTH TABLETS OF RUCAPARIB | 2015 |
|
RU2705156C2 |
| SOLID PREPARATIVE FORMS OF OSPEMIFENE | 2005 |
|
RU2423113C2 |
| ANTISENSE COMPOSITIONS AND METHODS FOR PRODUCTION AND USE THEREOF | 2009 |
|
RU2593939C2 |
| ORAL COMPOSITIONS OF CARDIAC SARCOMERE INHIBITORS | 2020 |
|
RU2823999C2 |
| IMMEDIATE RELEASE DOSAGE FORM | 2020 |
|
RU2795085C2 |
